Insider

Johnson & Johnson third-quarter 2026 earnings and operational results

Johnson & Johnson reported $25.4 billion in worldwide revenue for the third quarter, released on October 21, 2026. Net income was $210 million. Diluted earnings per share (EPS) fell to $0.09 from $2.12 a year earlier.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
Scientist in lab coat examines sample in laboratory
Photo by Navy Medicine on Unsplash
$25.4 billion
Quarterly revenue
$210 million
Net income
$0.09
Diluted EPS

Key points

  • Revenue grew 5.9% year-over-year to $25.4 billion for the period ended September 27, 2026.
  • Innovative Medicine segment sales rose 7.7% to $16.8 billion in the third quarter.
  • Biosimilar competition is expected to continue putting downward pressure on STELARA operational sales growth.

Third-quarter financial results

Revenue grew 5.9% year-over-year to $25.4 billion for the period ended September 27, 2026. Net income was $210 million. Third-quarter EPS declined 95.8%.

Quarter vs the same quarter a year earlier

Jun–Sep 2025Jun–Sep 2026Revenue+5.9%$24B$25.4BNet income-95.9%$5.2B$210M
Data from the original sources listed alongside.

Operational activity and policy changes

Innovative Medicine segment sales rose 7.7% to $16.8 billion in the third quarter. Biosimilar competition for STELARA negatively impacted the segment’s operational sales growth by approximately 6.9%.

The company also revised its 340B pricing policy. Covered entities must now submit claims data to receive discounts, and the choice of contract pharmacies is limited to one per facility.

Risks

Biosimilar competition is expected to continue putting downward pressure on STELARA operational sales growth.

What to watch

Shareholders should monitor the impact of biosimilar competition on Innovative Medicine sales in future reports. It is also important to observe whether the updated 340B policy affects product sales figures.

Original sources

  1. financial data (XBRL)October 21, 2026SHA-256 of our archived copy 27c0dd76a5a3…
  2. 10-Q filing, October 21, 2026October 21, 2026SHA-256 of our archived copy 5bcf6694e797…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards